QTERN
Total Payments
$4.9M
Transactions
598
Doctors
281
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $15,677 | 5 | 2 |
| 2019 | $577,189 | 43 | 21 |
| 2018 | $685,428 | 395 | 258 |
| 2017 | $3.6M | 155 | 3 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.9M | 254 | 99.7% |
| Food and Beverage | $9,424 | 342 | 0.2% |
| Consulting Fee | $2,450 | 1 | 0.0% |
| Travel and Lodging | $695.38 | 1 | 0.0% |
Payments by Type
Research
$4.9M
254 transactions
General
$12,569
344 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes | AstraZeneca Pharmaceuticals LP | $2.0M | 0 |
| A 16 week Single Center Randomized Double-Blind Active Controlled Parallel Group Phase 3b Trial to Evaluate the Efficacy of Saxagliptin Co administered with Dapagliflozin Compared to Dapagliflozin with Regard to Endogenous Glucose Production in Adult Patients with Type 2 Diabetes Who Have Insufficient Glycemic Control on Metformin or Metformin Sulfonyourea Therapy | AstraZeneca Pharmaceuticals LP | $1.4M | 0 |
| ICON project agreement SCOUT a phase three B study for subjects with moderate type two diabetes who have inadequate glycemic control on metformin | AstraZeneca UK Limited | $822,556 | 2 |
| ICON Project agreement Ireland scout phase 3 full service clinical trial outsourcing Saxa and Dapa vs Su bms CV181 36 | AstraZeneca UK Limited | $694,163 | 0 |
Top Doctors Receiving Payments for QTERN
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Lancaster, CA | $4.9M | 252 |
| , M.D | Endocrinology, Diabetes & Metabolism | Los Angeles, CA | $2,450 | 1 |
| , MD | Endocrinology, Diabetes & Metabolism | Williamstown, MA | $841.50 | 1 |
| , M.D | Pediatric Endocrinology | Sacramento, CA | $700.00 | 1 |
| , M.D | Internal Medicine | Baton Rouge, LA | $695.38 | 1 |
| , MD | Internal Medicine | Wheeling, IL | $490.86 | 4 |
| , MD | Internal Medicine | Elmhurst, IL | $205.04 | 2 |
| , MD | Internal Medicine | East Chicago, IN | $154.08 | 2 |
| , M.D | Internal Medicine | Gurnee, IL | $134.90 | 2 |
| , MD | Internal Medicine | Farmington Hills, MI | $134.11 | 1 |
| , M.D | Endocrinology, Diabetes & Metabolism | Lawrence, NY | $115.52 | 1 |
| , MD | Endocrinology, Diabetes & Metabolism | Evergreen Park, IL | $115.52 | 1 |
| , M.D | Endocrinology, Diabetes & Metabolism | Chicago, IL | $115.52 | 1 |
| , MD | Endocrinology, Diabetes & Metabolism | Elkhart, IN | $115.52 | 1 |
| , MD | Endocrinology, Diabetes & Metabolism | New Hyde Park, NY | $115.52 | 1 |
| , M.D., PHD | Endocrinology, Diabetes & Metabolism | Crystal Lake, IL | $115.52 | 1 |
| , MD | Endocrinology, Diabetes & Metabolism | Merrillville, IN | $115.52 | 1 |
| , MD | Endocrinology, Diabetes & Metabolism | Chicago, IL | $115.52 | 1 |
| , M.D | Endocrinology, Diabetes & Metabolism | Joliet, IL | $115.52 | 1 |
| , MD | Endocrinology, Diabetes & Metabolism | Williamsville, NY | $115.52 | 1 |
| , M. D | Endocrinology, Diabetes & Metabolism | Elmhurst, IL | $115.52 | 1 |
| , M.D | Internal Medicine | Louisville, KY | $112.71 | 1 |
| , M.D | Family Medicine | Hinsdale, IL | $105.69 | 1 |
| , D.O | Student in an Organized Health Care Education/Training Program | Ontario, CA | $103.43 | 1 |
| , M.D | Endocrinology, Diabetes & Metabolism | Edwardsville, IL | $103.43 | 1 |
Ad
Manufacturing Companies
- AstraZeneca Pharmaceuticals LP $3.4M
- AstraZeneca UK Limited $1.5M
Product Information
- Type Drug
- Total Payments $4.9M
- Total Doctors 281
- Transactions 598
About QTERN
QTERN is a drug associated with $4.9M in payments to 281 healthcare providers, recorded across 598 transactions in the CMS Open Payments database. The primary manufacturer is AstraZeneca Pharmaceuticals LP.
Payment data is available from 2017 to 2020. In 2020, $15,677 was paid across 5 transactions to 2 doctors.
The most common payment nature for QTERN is "Unspecified" ($4.9M, 99.7% of total).
QTERN is associated with 4 research studies, including "A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes" ($2.0M).